Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation
therapy. It is not yet known whether zoledronate combined with calcium is more effective than
calcium alone in preventing bone loss.
PURPOSE: Randomized phase III trial to compare the effectiveness of zoledronate combined with
calcium with that of calcium alone in preventing bone loss in patients with stage III or
stage IV prostate cancer who have received long-term androgen deprivation therapy.